Image sourceAn IntroductionNone of the 5 constituents in the Canadian Cannabis LPs Portfolio advanced this week, going down 6.1% on average and are now down 44.8%, on average, since Tuesday, April 30th, when the DEA announcement that it planned to follow through on the DHS recommendation that cannabis be reclassified from a Schedule I drug to a less stringently regulated Schedule III drug was met with an enthusiastic market response. In fact, the 5 stocks are now down 20.1% from where they were, on average, 8 weeks ago (i.e. from April 26th), before the announcement.Below are the details of the returns of the stocks in the munKNEE’s Canadian Cannabis LPs Portfolio, in descending order, for the week ending June 21st and for the last 8 weeks as well as any recent news, analyses and/or commentary where applicable.
- Organigram Establishes 7th international Supply Agreement
- Cronos Group Announces Expansion of GrowCo to Fuel Global Growth
- Why Tilray Brands Stock Has Dipped: Key Facts
- What’s the Fair Value Of Canopy Growth?
- Aurora Cannabis Q4 Financials Continue To Disappoint: Stock Declines
Average: down 6.1% this week; down 22% since April 26thConclusionThe Canadian cannabis LPs may well decline even further based on historical data (see here) so the question now is how much further it will drop before stabilizing. Time will tell. Stay tuned.More By This Author:
Aurora Cannabis Q4 Financials Continue To Disappoint: Stock Declines
Micro/Small Cap AI Stocks Portfolio Has Tumbled 9.5% So Far This June
The 6 Segments Of The Semiconductor Value Chain Now Up 31% YTD
Leave A Comment